Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Wins Second Service Contract with USC; Sets Date for 04 Annual Meeting to Vote on Solexa Merger

The date of Lynx's shareholder meeting is March 1, not March 21.

NEW YORK, Jan. 31 (GenomeWeb News) - Researchers at the University of Southern California will continue to use Lynx's gene-expression technology to study oyster larval development after winning a new grant from the National Science Foundation, Lynx said today.

 

Under the new agreement with USC, Lynx will be paid for performing genome-wide transcriptome sequencing services on oyster samples, using its massive parallel signature sequencing technology.

 

Separately, Lynx said it will hold its 2004 annual meeting of stockholders on March 1, where shareholders will vote on the proposed merger with Solexa.

 

Lynx also said it will have a hearing before a Nasdaq listing qualifications panel on Feb. 9 to review Nasdaq's decision to delist the company from the Nasdaq SmallCap Market after Lynx failed to hold an annual stockholder meeting by Dec. 31, 2004.

 

"We believe that following the upcoming stockholders' meeting, Lynx will again be in full compliance with Nasdaq listing requirements," acting CEO Mary Schramke said in a statement today.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.